DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection
2017; Elsevier BV; Volume: 17; Issue: 6 Linguagem: Inglês
10.1016/s1473-3099(17)30139-1
ISSN1474-4457
AutoresMihály Sulyok, Thomas Rückle, Alexandra Roth, Raymund Egid Mürbeth, Stephan Chalon, Nicola Kerr, Sonia Schnieper Samec, Nathalie Gobeau, Carlos Lamsfus Calle, Javier Ibáñez, Zita Sulyok, Jana Held, Tamirat Gebru, Patricia Granados, Sina Brückner, Christian N. Nguetse, Juliana Boex Mengue, Albert Lalremruata, B. Kim Lee Sim, Stephen L. Hoffman, Jörg J. Möhrle, Peter G. Kremsner, Benjamin Mordmüller,
Tópico(s)Parasites and Host Interactions
ResumoA drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substantially advance malaria control. DSM265 is an experimental antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase. DSM265 shows in vitro activity against liver and blood stages of P falciparum. We assessed the prophylactic activity of DSM265 against controlled human malaria infection (CHMI).
Referência(s)